Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy | Zendy

Frank A. Sinicrope | Zendy; Michelle R. Mahoney | Zendy; Thomas C. Smyrk | Zendy; Stephen N. Thibodeau | Zendy; Robert S. Warren | Zendy; Monica M. Bertagnolli | Zendy; Garth D. Nelson | Zendy; Richard M. Goldberg | Zendy; Daniel J. Sargent | Zendy; Steven R. Alberts | Zendy

Open Access

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Author(s) -

Frank A. Sinicrope,

Michelle R. Mahoney,

Thomas C. Smyrk,

Stephen N. Thibodeau,

Robert S. Warren,

Monica M. Bertagnolli,

Garth D. Nelson,

Richard M. Goldberg,

Daniel J. Sargent,

Steven R. Alberts

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2013.48.9591

Subject(s) - medicine , folfox , colorectal cancer , kras , oncology , oxaliplatin , cetuximab , hazard ratio , cancer , chemotherapy , confidence interval

The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research